The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases

Authors

  • Ingrid M. E. Desar Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • Sasja F. Mulder Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • Alexander B. Stillebroer Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • Dick-Johan van Spronsen Department of Internal Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
  • Winette T. A. van der Graaf Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • Peter F. A. Mulders Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
  • Carla M. L. van Herpen Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

DOI:

https://doi.org/10.1080/02841860902974167

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2009-01-01

How to Cite

Desar, I. M. E., Mulder, S. F., Stillebroer, A. B., van Spronsen, D.-J., van der Graaf, W. T. A., Mulders, P. F. A., & van Herpen, C. M. L. (2009). The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncologica, 48(6), 927–931. https://doi.org/10.1080/02841860902974167

Issue

Vol. 48 No. 6 (2009): Acta Oncologica

Section

Articles